Navigation Links
CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007

ROCKVILLE, Md., April 4, 2007 -- CytImmune, a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies has been selected to present a poster abstract at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago Illinois, June 1-5. The poster session will take place from 8:00 am to 12 noon on June 3. Dr. Lawrence Tamarkin, CEO of CytImmune will present the poster abstract entitled "Preliminary Results of a Phase I clinical trial of CYT-6091: A pegylated colloidal gold TNF nanomedicine.


"Acceptance to ASCO provides CytImmune the opportunity to present its research to the leading body of international oncology experts," said Dr. Lawrence Tamarkin, CEO of CytImmune Sciences. "For an emerging company, it's a chance interact with those in the field, advance science and demonstrate our role in the fight against cancer."


CYT-6091 (Aurimune), CytImmune's lead drug compound, is recombinant human tumor necrosis factor alpha (TNF) bound to the surface of 27 nanometer pegylated colloidal gold nanoparticles. While TNF's tumor killing properties are well documented, its clinical use has been severely limited due to unacceptable toxicities. To harness the potential of this anti-cancer agent, CytImmune's approach simultaneously binds PEG-Thiol and TNF to the surface of colloidal gold nanoparticles, whose design is to: (1) make them invisible to immune detection, thereby avoiding uptake by the liver and spleen and (2) target delivery of TNF directly to tumor sites. At 27 nanometers in size, CYT-6091 is able to exit the blood stream through leaky blood vessels and sequester in and around tumor sites with TNF binding to available receptors in this area. Preclinical studies indicate that CYT-6091 is then able to actively and passively target tumors, potentially delivering more drug to the site of disease with reduced side effects. The mechanism of targeting solid tumor s is independent of tumor type. Phase I clinical trials for CYT-6091 (Aurimune) began in May 2006 at the NCI Center for Cancer Research, Bethesda, MD.


Phase I preliminary trial data will be released according to ASCO's Abstract Policy, in which the information is confidential from the time of submission until the time the information is made publicly available at the ASCO Annual Meeting. The American Society of Clinical Oncology Annual Meeting is considered the premier educational and scientific event in the oncology community. In 2006, more than 29,000 attendees from around the world participated in the 42nd ASCO annual meeting in Atlanta, Georgia.


ABOUT CYTIMMUNE

CytImmune Sciences is a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies harnessing the unique properties of gold nanoparticles, known anti-cancer agents and biology of tumors. The platform technology allows for the targeted delivery of anti-caner therapies while avoiding update by healthy organs and tissues leading to improved efficacy, safety and patient outcomes. CytImmune hopes to build from this common core technology a family of therapeutics with faster development timelines, efficient regulatory approvals, new commercialization value, and greater patient benefits.



Contact:
Alicia Moran
703-739-2424x110
'"/>




Related medicine technology :

1. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... A new Transparency Market Research report states ... at US$0.53 bn in 2013 and is predicted to touch US$2.38 ... 2014 and 2022. The title of the report is "Non-invasive Prenatal ... Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred to as ...
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in ... medical device technologies. BCC Research reveals in its new report ... region, should see strong growth due to rising government healthcare spending, ... Continue Reading ... ...
(Date:1/23/2017)... January 23, 2017 The global  anxiety disorders and depression ... 2025. The rising incidence of depression worldwide is anticipated to drive the market ... in the declining demand for antidepressants in the recent years. ... ... View Research Logo ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... with the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education ... of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high ...
(Date:1/23/2017)... ... ... “The Inn at the Mill”: a story of love and redemption, hope and uncertainty ... and content. , “The Inn at the Mill” is the creation of published author, ... and is now living in Berks County on Crow Hill. The inn, the ...
(Date:1/23/2017)... VA (PRWEB) , ... January ... ... Nutrition Partnership (SNP) has launched online education programs and resources at seafoodnutrition.org/programs ... and nutritional benefits of a seafood-rich diet. These resources have been developed ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of Christ”: ... “Some Infallible Characteristics of Christ” is the creation of published author, Rev. Dr. Robert ... Church for thirteen years, a preacher for over nineteen, a pastor for over fifteen ...
(Date:1/22/2017)... ... January 22, 2017 , ... Phytocéane invites clients to take ... rest of the world with ZANZIBAR MILKY CREAM. Inspired by the beauty of Zanzibar, ... Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, velvety body cream ...
Breaking Medicine News(10 mins):